Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination.
A comparative study of two smallpox vaccines, standard calf lymph vaccine, and an attenuated vaccine, CVI-78, was performed in 95 children. Primary vaccination with CVI-78 resulted in a more attenuated response than primary vaccination with standard vaccine. Sixty-one percent of those vaccinated with CVI-78 and 96 percent of those vaccinated with standard vaccine developed a major dermal reaction; 16 percent of those vaccinated with CVI-78 and 89 percent of those vaccinated with standard vaccine developed post-vaccination neutralizing antibodies. Twenty-seven percent of the children vaccinated with CVI-78 demonstrated neither a dermal nor serologic postvaccination response, whereas only 2 percent of those vaccinated with standard vaccination demonstrated no postvaccination response.
D000482:Allantois / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D001768:Blister / Q000209:etiology / Q000517:prevention & control; D002417:Cattle; D002675:Child, Preschool; D002823:Chorion / Q000276:immunology; D002921:Cicatrix; D005500:Follow-Up Studies; D006385:Hemagglutination Inhibition Tests; D006462:Hemolytic Plaque Technique; D006801:Humans; D007223:Infant; D009500:Neutralization Tests; D012867:Skin / Q000276:immunology; D012899:Smallpox / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000009:adverse effects; D014481:United States; D014611:Vaccination / Q000379:methods; D014613:Vaccines, Attenuated / Q000009:adverse effects
D000914:Antibodies, Viral; D012900:Smallpox Vaccine; D014613:Vaccines, Attenuated